Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
Zevra Therapeutics (NASDAQ: ZVRA) said its executive leadership will present at the J.P.
Rhea-AI Summary
Zevra Therapeutics (NASDAQ: ZVRA) said its executive leadership will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 15, 2026 at 9:45 a.m. PT. Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations "Events & Presentations" page at investors.zevra.com.
Details
News Market Reaction – ZVRA
On Jan 8, the day this news came out, ZVRA closed 1.77% above the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference number
- Presentation date
- January 15, 2026
- Scheduled conference presentation
- Presentation time
- 9:45 a.m. PT
- Investor presentation slot at conference
Historical Context
-
Exclusive MIPLYFFA access deal with Uniphar for select ex-Europe territories.
-
Stock option grants to new employees under inducement award plan.
-
Appointment of Alicia Secor and retirement of director Wendy Dixon.
-
Announcement of CFO R. LaDuane Clifton’s planned resignation.
-
Strong revenue growth and sharply lower net loss for Q3 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.